Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS

Journal of Molecular and Cellular Cardiology

Volumn 66, Issue , 2014, Pages 167-176

  Patel, Vaibhav B ^a,b   Clarke, Nicola ^c   Wang, Zuocheng ^a,b   Fan, Dong ^b,d   Parajuli, Nirmal ^a,b   Basu, Ratnadeep ^a,b   Putko, Brendan ^a,b   Kassiri, Zamaneh ^b,d   Turner, Anthony J ^c   Oudit, Gavin Y ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin converting enzyme 2; Angiotensin II; Renin angiotensin system; TNF converting enzyme

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE DELETION; HEART DISEASE; HEART MUSCLE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; UPREGULATION; WESTERN BLOTTING;

ACE; ANG; ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR; AT1R; HEART FAILURE; HF; KNOCKOUT; KO; P38 MAPK; P38 MITOGEN ACTIVATED PROTEIN KINASE; RAS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; ROS; TACE; TNF-Α CONVERTING ENZYME; TUMOR NECROSIS FACTOR-Α CONVERTING ENZYME;

ADAM PROTEINS; ANGIOTENSIN II; ANIMALS; CELL LINE; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIUM; NADPH OXIDASE; PEPTIDYL-DIPEPTIDASE A; PROTEIN TRANSPORT; PROTEOLYSIS; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84891683755     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.11.017     Document Type: Article

References (43)

1. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:C82-C97.
2. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730-1736.
3. Serneri G.G., Boddi M., Cecioni I., Vanni S., Coppo M., Papa M.L., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001, 88:961-968.
4. Dell'Italia L.J. Translational success stories: angiotensin receptor 1 antagonists in heart failure. Circ Res 2011, 109:437-452.
5. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000, 87:E1-E9.
6. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000, 275:33238-33243.
7. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-828.
8. Patel V.B., Bodiga S., Basu R., Das S.K., Wang W., Wang Z., et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res 2012, 110:1322-1335.
9. Zhong J., Basu R., Guo D., Chow F.L., Byrns S., Schuster M., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010, 122:717-728.
10. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005, 111:2605-2610.
11. Kassiri Z., Zhong J., Guo D., Basu R., Wang X., Liu P.P., et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2009, 2:446-455.
12. Bodiga S., Zhong J.C., Wang W., Basu R., Lo J., Liu G.C., et al. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc Res 2011, 91:151-161.
13. Der Sarkissian S., Grobe J.L., Yuan L., Narielwala D.R., Walter G.A., Katovich M.J., et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008, 51:712-718.
14. Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Semin Cell Dev Biol 2009, 20:138-145.
15. Chang C., Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001, 11:S37-S43.
16. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008, 8:929-941.
17. Patel V.B., Wang Z., Fan D., Zhabyeyev P., Basu R., Das S.K., et al. Loss of p47phox subunit enhances susceptibility to biomechanical stress and heart failure because of dysregulation of cortactin and actin filaments. Circ Res 2013, 112:1542-1556.
18. Swendeman S., Mendelson K., Weskamp G., Horiuchi K., Deutsch U., Scherle P., et al. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res 2008, 103:916-918.
19. Basu R., Oudit G.Y., Wang X., Zhang L., Ussher J.R., Lopaschuk G.D., et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 2009, 297:H2096-H2108.
20. Kassiri Z., Oudit G.Y., Sanchez O., Dawood F., Mohammed F.F., Nuttall R.K., et al. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 2005, 97:380-390.
21. Epelman S., Tang W.H., Chen S.Y., Van Lente F., Francis G.S., Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008, 52:750-754.
22. Xu P., Derynck R. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell 2010, 37:551-566.
23. Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005, 280:30113-30119.
24. Lambert D.W., Clarke N.E., Hooper N.M., Turner A.J. Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett 2008, 582:385-390.
25. Scott A.J., O'Dea K.P., O'Callaghan D., Williams L., Dokpesi J.O., Tatton L., et al. Reactive oxygen species and p38 mitogen-activated protein kinase mediate tumor necrosis factor alpha-converting enzyme (TACE/ADAM-17) activation in primary human monocytes. J Biol Chem 2011, 286:35466-35476.
26. Schafer B., Marg B., Gschwind A., Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 2004, 279:47929-47938.
27. Gschwind A., Zwick E., Prenzel N., Leserer M., Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001, 20:1594-1600.
28. Alfa Cisse M., Sunyach C., Slack B.E., Fisher A., Vincent B., Checler F. M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity. J Neurosci 2007, 27:4083-4092.
29. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
30. Lassegue B., San Martin A., Griendling K.K. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 2012, 110:1364-1390.
31. Landmesser U., Cai H., Dikalov S., McCann L., Hwang J., Jo H., et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-515.
32. Grote K., Ortmann M., Salguero G., Doerries C., Landmesser U., Luchtefeld M., et al. Critical role for p47phox in renin-angiotensin system activation and blood pressure regulation. Cardiovasc Res 2006, 71:596-605.
33. Wang W., Bodiga S., Das S.K., Lo J., Patel V., Oudit G.Y. Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev 2012, 17:683-691.
34. Epelman S., Shrestha K., Troughton R.W., Francis G.S., Sen S., Klein A.L., et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 2009, 15:565-571.
35. Lew R.A., Warner F.J., Hanchapola I., Yarski M.A., Manohar J., Burrell L.M., et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008, 93:685-693.
36. Ferrario C.M., Jessup J., Gallagher P.E., Averill D.B., Brosnihan K.B., Ann Tallant E., et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005, 68:2189-2196.
37. Bendall J.K., Cave A.C., Heymes C., Gall N., Shah A.M. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002, 105:293-296.
38. Doerries C., Grote K., Hilfiker-Kleiner D., Luchtefeld M., Schaefer A., Holland S.M., et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007, 100:894-903.
39. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
40. Xia H., Sriramula S., Chhabra K.H., Lazartigues E. Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. Circ Res 2013, 113:1087-1096.
41. Sekiguchi K., Li X., Coker M., Flesch M., Barger P.M., Sivasubramanian N., et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res 2004, 63:433-442.
42. Rutschow S., Li J., Schultheiss H.P., Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 2006, 69:646-656.
43. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010, 45:146-169.